Macrogenics Profit Margin

The latest profit margin for MGNX is -8.7% as of June 2026. That compares with -22.21% in the prior-year period — up 60.8% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Macrogenics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MGNX's profit margin moved from -22.21% to -8.7% — a 60.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Macrogenics's valuation or profitability profile.

Against Healthcare companies, MGNX currently prints -8.7% for profit margin, while the sector average sits near 13.76%. That is roughly 163.2% below the sector mean. Large gaps often invite a closer look at Macrogenics's growth, margins, and balance sheet.

Profit Margin shows how effectively Macrogenics converts resources into returns. At -8.7%, MGNX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -22.21% in the prior-year period — up 60.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MGNX's profit margin (-8.7%), review year-over-year change from -22.21%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.